Key result
Inhibition of STAT3 or blockade of IL-6 failed to alter disease development in the LCWE mouse model of Kawasaki disease, indicating they may be bystanders of inflammation.
Why the study?
10% of Kawasaki disease patients are resistant to front-line therapy, and interventions to address secondary complications such as myocardial fibrosis are lacking.
Does inhibition of IL-6 or STAT3 attenuate vasculitis in the LCWE mouse model of Kawasaki disease?
Population
5-week-old male mice
Comparison
LCWE alone vs LCWE with anakinra, STAT3 inhibitor, or anti-IL-6R antibody vs saline controls
Design
Preclinical animal model study
Authors
Loading...
IL-6/STAT3 inhibition does not attenuate vasculitis in this model; leaves open their role as drivers in human Kawasaki disease.
Does inhibition of IL-6 or STAT3 attenuate vasculitis in the LCWE mouse model of Kawasaki disease?
Inhibition of IL-6 or STAT3 fails to attenuate vasculitis in a mouse model of Kawasaki disease, indicating they may be bystanders rather than drivers of inflammation.
Porritt et al. (2021) studied Kawasaki disease (mouse model). STAT3 small molecular inhibitor and anti-IL-6R antibody vs. LCWE alone or saline was evaluated on Disease development. Inhibition of STAT3 or blockade of IL-6 failed to alter disease development in the LCWE mouse model of Kawasaki disease, indicating they may be bystanders of inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: